Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer
NCT04221945Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2020
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
A Phase 3 trial of pembrolizumab in Cervical Cancer (CC), sponsored by Merck & Co.. Started May 2020; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04221945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221945.